Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

4-Traders Homepage  >  Equities  >  Nasdaq  >  Acorda Therapeutics Inc    ACOR

 SummaryQuotesChartsNewsAnalysisCalendarCompanyFinancialsConsensusRevisions 
Quotes 5-day view   Delayed Quote. Delayed Nasdaq
06/19/2017 06/20/2017 06/21/2017 06/22/2017 06/23/2017 Date
17.8(c) 18.15(c) 18.7(c) 18.65(c) 19.45(c) Last
574 554 946 882 1 182 075 1 169 206 1 213 774 Volume
+3.19% +1.97% +3.03% -0.27% +4.29% Change
More quotes
Financials ($)
Sales 2017 566 M
EBIT 2017 81,2 M
Net income 2017 44,6 M
Debt 2017 178 M
Yield 2017 -
Sales 2018 502 M
EBIT 2018 65,7 M
Net income 2018 2,94 M
Debt 2018 57,5 M
Yield 2018 -
P/E ratio 2017 25,16
P/E ratio 2018 101,97
EV / Sales2017 1,85x
EV / Sales2018 1,85x
Capitalization 870 M
More Financials
Company
Acorda Therapeutics, Inc. develops and markets therapeutic products for nervous system disorders.The company's two main products are Ampyra and Zanaflex Capsules.The Ampyra is an oral drug, which treats to improve walking in patients with multiple sclerosis and Zanaflex Capsules, which is a short... 
More about the company
Surperformance© ratings of Acorda Therapeutics Inc
Trading Rating : Investor Rating :
More Ratings
Latest news on ACORDA THERAPEUTICS INC
06/15 ACORDA THERAPEUTICS : Presenting New Tozadenant Data at 2017 MDS Congress
06/09 ACORDA THERAPEUTICS : to Present at the Goldman Sachs Healthcare Conference
06/09 ACORDA THERAPEUTICS INC : Other Events (form 8-K)
06/06 ACORDA THERAPEUTICS : Climbs on New Data Presented to Conference
06/06 ACORDA THERAPEUTICS : Presenting New Tozadenant Data at 2017 MDS Congress
06/05 ACORDA THERAPEUTICS INC : Other Events, Financial Statements and Exhibits (form ..
06/05 ACORDA THERAPEUTICS : CVT-301 Phase 3 Data Showed Significantly Improved Motor F..
06/01 ACORDA THERAPEUTICS, INC. (NASDAQ : ACOR) Files An 8-K Submission of Matters to ..
06/01 ACORDA THERAPEUTICS INC : Submission of Matters to a Vote of Security Holders (f..
05/31 ACORDA THERAPEUTICS : to Present at the Goldman Sachs Healthcare Conference
More news
Sector news : Bio Therapeutic Drugs
06/23DJOne of the Last Untapped Blockbuster Diseases? Drug Companies Race to Find a ..
06/20 Novartis eye drug works with fewer injections than rival
06/15DJACTELION : J&J Maps Research Plans for Actelion -- WSJ
06/14DJACTELION : Correction to J&J Actelion Story
06/14DJACTELION : J&J Plans to Add Drug Discovery and Early Research to Actelion Unit
More sector news : Bio Therapeutic Drugs
Latest Tweets
06/23Get the latest news and updates for $WX $DD $ABB $ACOR $MITL automatically wi.. 
06/22State Board of Administration of Florida Retirement System Has $709,000 Stake.. 
06/22Acorda Therapeutics, Inc. $ACOR Insider Ron Cohen Acquires 20,000 Shares of S.. 
06/21Biotech Insider Just Loaded Up $234 Million Worth the Stock  
06/20$ACOR .. FORM 4 .,. CEO P 20,000 A $ 16.9499 
More tweets
Qtime:16
News from SeekingAlpha
06/09 Acorda continues its defense of Ampyra patents against generic competitors, a..
06/06 Acorda Therapeutics (ACOR) Presents Parkinson's Disease Drug Overview - Slide..
06/06 PREMARKET GAINERS AS OF 9 : 05 am
06/05 Acorda Therapeutics +8.5% on positive results in Parkinson's disease drug
06/05 After Hours Gainers / Losers
Advertisement
Chart ACORDA THERAPEUTICS INC
Duration : Period :
Acorda Therapeutics Inc Technical Analysis Chart | ACOR | US00484M1062 | 4-Traders
Full-screen chart
Technical analysis trends ACORDA THERAPEUTI...
Short TermMid-TermLong Term
TrendsBullishBearishBearish
Technical analysis
Income Statement Evolution
More Financials
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 7
Average target price 28,5 $
Spread / Average Target 53%
Consensus details
EPS Revisions
More Estimates Revisions
Managers
NameTitle
Ronald Cohen President, Chief Executive Officer & Director
David Lawrence Chief Financial & Accounting Officer
Andrew R. Blight Chief Scientific Officer
Anthony O. Caggiano Vice President-Research & Development
Richard P. Batycky Chief Technology Officer
More about the company
Sector and Competitors
1st jan.Capitalization (M$)
ACORDA THERAPEUTICS IN..-0.80%870
AMGEN18.88%127 827
CELGENE CORPORATION15.49%104 381
GILEAD SCIENCES-1.58%92 098
REGENERON PHARMACEUTIC..42.20%55 965
VERTEX PHARMACEUTICALS83.02%33 756
More Results